CeleCor Therapeutics
Private Company
Funding information not available
Overview
CeleCor Therapeutics is advancing zalunfiban, a subcutaneous GPIIb/IIIa inhibitor, to treat STEMI heart attacks at the first point of medical contact. The drug is engineered for rapid onset (maximal effect within 15 minutes) and a predictable, short duration of action, making it suitable for use by paramedics and in emergency departments. The company has completed enrollment in its pivotal Phase 3 CeleBrate trial, positioning it for a potential near-term regulatory filing if results are positive. CeleCor is targeting a significant unmet need, as a large proportion of STEMI patients do not receive timely antiplatelet therapy per guidelines, leading to worse outcomes.
Technology Platform
Engineering of small molecule GPIIb/IIIa inhibitors optimized for subcutaneous administration, with rapid onset (15 min to max effect) and short, predictable duration (~2-4 hours) of antiplatelet action.
Opportunities
Risk Factors
Competitive Landscape
Zalunfiban competes in the antiplatelet space, but its pre-hospital, subcutaneous positioning is novel. It faces competition from established oral P2Y12 inhibitors (ticagrelor, prasugrel) and intravenous GPIIb/IIIa inhibitors (eptifibatide, tirofiban), which are used primarily in-hospital. Its key differentiator is speed and ease of administration in the field.